在阿尔茨海默氏病的酸化
Julia Telser1, Kirsten Grossmann1, Niklas Wohlwend2
1Faculty of Medical Science, Private University in the Principality of Liechtenstein, Triesen, Liechtenstein; Laboratory Dr. Risch, Vaduz, Liechtenstein.
Advances in clinical chemistry
|October 18, 2023
概括
化质蛋白 (p-tau) 显示出作为阿尔茨海默病 (AD) 血液生物标志物的前景. 不同的p-tau异型可以准确地检测AD的阶段,并与其他神经退行性疾病区分开来,有助于诊断.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 目前阿尔茨海默病 (AD) 诊断依赖于侵入性脑脊液生物标志物或昂贵的PET扫描.
- 化的蛋白 (p-tau) 正在成为阿尔茨海默病的血基生物标志物,其侵袭性较小.
- 本综述的重点是血酸化在氨酸181 (p-tau181),氨酸217 (p-tau217) 和氨酸231 (p-tau231) 的氨酸.
结论:
- 血p-tau生物标志物 (p-tau181,p-tau217,p-tau231) 是用于诊断阿尔茨海默氏病在其连续性的信息.
- 这些生物标志物反映了潜在的AD病理,疾病进展和大脑结构变化.
- 需要进一步的研究来标准化测试,并建立临床切断点,以便广泛采用.
相关概念视频
Phosphorylation
50.4K
The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
50.4K
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Protein Kinases and Phosphatases
13.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.2K


